Shares of Hims & Hers Health plunged as much as 10.7% to $29.23 on July 24 as traders locked in profits from a sharp multi-week rally and braced for the outcome of a pivotal FDA advisory panel on peptide compounding — only to see that very panel deliver a surprise favorable vote hours later. The sell-the-news reaction collided with a buy-the-rumor reversal, crystallizing the binary bet that HIMS has become.
• The FDA Panel Defied Its Own Staff — And That Changes the Game
The Pharmacy Compounding Advisory Committee voted 8–6 in favor of recommending BPC-157, the most commercially significant peptide under review, for addition to the federal 503A Bulk Drug Substances List.
The positive vote defied expectations — prior FDA briefing documents had raised safety questions and suggested a likely rejection.
The recommendation is not FDA approval and still requires formal agency rulemaking , meaning revenue is months away at best.
• A $20 Billion Market Is Opening, But Hims Needs Every Dollar
Canaccord Genuity estimates the compounded peptide market (excluding weight-loss drugs) could reach roughly $20 billion within three to five years, and calculates that "every 1% share of the estimated market would yield about $200 million in incremental revenue for HIMS." That matters because the company posted a $92 million Q1 loss as it transitions away from compounded weight-loss drugs, on revenue of $608 million that missed Wall Street estimates. Peptides are now the clearest path to replacing lost high-margin compounding income.
• Insiders and Analysts Are Sending Mixed Signals
CFO Oluyemi Okupe sold 7,163 shares at roughly $32 apiece days before the vote, pocketing $229,000, though he retained over 284,000 shares. On the analyst side, BofA raised its price target to $36 from $25, while Canaccord Genuity maintains a Buy at $40.
Citi upgraded its target to $35 from $28 , but flagged risk ahead of the August 10 earnings report.
• The Real Test Is Execution, Not Regulation
Hims acquired a U.S.-based peptide manufacturing facility in 2025 and maintains a compounding footprint exceeding one million square feet.
Management raised full-year 2026 revenue guidance to $2.8–$3.0 billion. But gross margins already compressed to 65% from 73% a year earlier, and adjusted EBITDA fell to $44.3 million from $91.1 million. Turning a regulatory green light into actual profit — before margins erode further — is the question shareholders are now paying a premium to answer.